ROYALTY PHARMA PLC- CL A (RPRX) Stock Analyst Ratings
USA - NASDAQ:RPRX - GB00BMVP7Y09 - Common Stock
39.59 USD
+0.63 (+1.62%)
40.7166 USD
+1.13 (+2.85%)
ChartMill assigns a Buy % Consensus number of 83% to RPRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 44.35. This target is 12.04% above the current price.
RPRX was analyzed by 15 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about RPRX.
In the previous month the buy percentage consensus was at a similar level.
RPRX was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-30 | Goldman Sachs | Initiate | Buy |
| 2025-07-22 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-10-25 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-14 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-07-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-06-03 | UBS | Downgrade | Buy -> Neutral |
| 2024-04-12 | B of A Securities | Maintains | Buy -> Buy |
| 2024-02-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-02-20 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-11-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-10-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-08-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-07-11 | Morgan Stanley | Reiterate | Overweight -> Overweight |
| 2023-05-10 | Morgan Stanley | Maintains | Overweight |
| 2023-04-10 | Morgan Stanley | Maintains | Overweight |
| 2023-02-16 | UBS | Maintains | Buy |
| 2022-12-06 | Morgan Stanley | Maintains | Overweight |
| 2022-11-09 | Morgan Stanley | Maintains | Overweight |
| 2022-10-18 | JP Morgan | Maintains | Overweight |
| 2022-08-08 | Morgan Stanley | Maintains | Overweight |
| 2022-07-14 | Tigress Financial | Maintains | Buy |
| 2022-06-14 | UBS | Initiate | Buy |
| 2022-05-13 | ScotiaBank | Initiate | Outperform |
| 2022-04-27 | Goldman Sachs | Initiate | Buy |
| 2022-04-14 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2021-10-29 | Citigroup | Upgrade | Neutral -> Buy |
| 2021-08-16 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-07-30 | Tigress Financial | Initiate | Buy |
ROYALTY PHARMA PLC- CL A / RPRX FAQ
What do analysts expect the price target to be for ROYALTY PHARMA PLC- CL A (RPRX)?
15 analysts have analysed RPRX and the average price target is 44.35 USD. This implies a price increase of 12.04% is expected in the next year compared to the current price of 39.59.
What is the consensus rating for ROYALTY PHARMA PLC- CL A (RPRX) stock?
The consensus rating for ROYALTY PHARMA PLC- CL A (RPRX) is 82.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed ROYALTY PHARMA PLC- CL A (RPRX)?
The number of analysts covering ROYALTY PHARMA PLC- CL A (RPRX) is 15.